Vanda Pharmaceuticals
VNDA
86 hedge funds and large institutions have $393M invested in Vanda Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 33 closing their positions.
110% more call options, than puts
Call options by funds: $36M | Put options by funds: $17.1M
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
13% more capital invested
Capital invested by funds: $348M → $393M (+$45.7M)
13% less funds holding
Funds holding: 99 → 86 (-13)
39% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.9M |
| 2 |
O
OrbiMed
New York
|
+$9.94M |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$4.02M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$3.32M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$9.51M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.12M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$5.94M |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
-$5.33M |
| 5 |
Jennison Associates
New York
|
-$4.94M |
VNDA Hedge Fund Activity: Q4 2013 in Review
86 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2013, worth a combined $393M — up 13% from $348M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of VNDA and 20 opened new positions — a net loss of 13 holders — while 21 trimmed existing stakes and 35 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $11.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.51M sold.
- 86 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2013, down from 99 in Q3 2013.
- Funds reported $393M of Vanda Pharmaceuticals stock for Q4 2013, up 13% quarter-over-quarter.
- 20 funds opened new Vanda Pharmaceuticals positions in Q4 2013 and 33 closed out, a net change of -13 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2013 was T. Rowe Price Associates, an estimated $11.9M added.
- The largest Vanda Pharmaceuticals seller in Q4 2013 was Perceptive Advisors, an estimated $9.51M sold.
Based on aggregated 13F filings for Q4 2013.